drugset / Trial / NCT03131453
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Phase 2/3
Terminated
1145 enrolled
Novartis Pharmaceuticals
Amgen · collabBanner Alzheimer's Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Timeline
- Start
- 2017-08-03
- Primary completion
- 2020-03-26
- Completion
- 2020-03-26
Outcome
Outcome not reported
Stopped: “The study was terminated due to safety issues.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNP520 | Unknown | 15 mg | Oral |
| Subject | CNP520 | Unknown | 50 mg | Oral |